Anticancer agent 310
Anticancer agent 310 is an antitumor agent. Anticancer agent 310 releases nitric oxide to induce mitochondrial ROS burst, triggers mitochondrial dysfunction and activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 apoptotic pathway. Anticancer agent 310 also reduces the levels of SHMT2 and MTHFD2, decreases the ratios of NADPH/NADP+ and GSH/GSSG, thereby disrupting redox homeostasis and exacerbating intracellular ROS accumulation. Anticancer agent 310 can be used in research related to gastric cancer.
For research use only. We do not sell to patients.
- Formula: C33H36N2O12S
- Molecular Weight:684.71
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
Anticancer agent 310 (compound A9) (0.016-10 μM; 72 h) potently inhibits the proliferation of various human and murine tumor cell lines in vitro[1].
Anticancer agent 310 (1.6-40 nM; 12-14 days) inhibits the long-term colony-forming ability of HGC27 and AGS gastric cancer cells in a concentration-dependent manner[1].
Anticancer agent 310 (50-100 μM; 2 h) releases nitric oxide in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (2 μM; 12 h) induces mitochondrial ROS burst in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (2 μM) induces mitochondrial membrane potential depolarization in HGC27 and AGS gastric cancer cells, and this effect is reversed by ROS scavenging[1].
Anticancer agent 310 (2 μM; 36 h) induces apoptosis in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (0.5-2 μM; 24 h) activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 mitochondrial apoptotic pathway in HGC27 and AGS gastric cancer cells in a dose-dependent manner in vitro[1].
Anticancer agent 310 (0.5-2 μM; 24 h) downregulates SHMT2 and MTHFD2, key enzymes in the folate one-carbon metabolic pathway, in HGC27 and AGS gastric cancer cells in a dose-dependent manner by inhibiting the transcription factor ATF4[1].
Anticancer agent 310 (2 μM; 12 h) disrupts redox homeostasis in HGC27 and AGS gastric cancer cells and reduces the ratios of NADPH/NADP+ and GSH/GSSG[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7, HepG2, HCT-116, HGC27, U251, AGS, ES-2, A2780, K562, MEG01, CT26
-
Concentration:0.016, 0.08, 0.4, 2, 5, 10 μM
-
Incubation Time:72 h
-
Result:Exhibited sub-micromolar inhibitory activity across all tested cell lines, with IC50 values as follows: MCF-7: 0.19 μM; HepG2: 0.21 μM; HCT-116: 0.22 μM; HGC27: 0.10 μM; U251: 0.14 μM; AGS: 0.02 μM; ES-2: 0.12 μM; A2780: 0.11 μM; K562: 0.12 μM; MEG01: 0.40 μM; CT26: 0.26 μM.
-
Cell Line:HGC27, AGS
-
Concentration:2 μM
-
Incubation Time:36 h
-
Result:Increased total apoptotic cells in HGC27 cells from 10.99% (control) to 83.1%.
Induced a total apoptotic rate of 60.9% in AGS cells.
-
Cell Line:HGC27, AGS
-
Concentration:0.5, 1, 2 μM
-
Incubation Time:24 h
-
Result:Upregulated the expression of cytoplasmic cytochrome c, Bax, Cleaved Caspase-9, and Cleaved Caspase-3, and downregulated the expression of mitochondrial cytochrome c and Bcl-2 in a dose-dependent manner in both HGC27 and AGS cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCG mice treated HGC27 tumor fragments[1]
-
Dosage:5 mg/kg; 10 mg/kg; 15 mg/kg
-
Administration:intratumoral; daily; 14 days
-
Result:Reduced tumor weight relative to control at 5 mg/kg dose.
Achieved 95.3% tumor growth inhibition (TGI), with 4 out of 6 mice showing complete tumor regression at 10 mg/kg dose.
Achieved 98.78% TGI, with 5 out of 6 mice showing complete tumor regression at 15 mg/kg dose.
Decreased expression of Ki67, SHMT2, and MTHFD2 in tumor tissues relative to control group at 10 mg/kg and 15 mg/kg doses.
Caused no obvious body weight loss or mortality in any dose group.
Chemical Information
-
Molecular Weight 684.71
-
Formula C33H36N2O12S
-
SMILES
O=C1OCC2=C1CC[C@@]3(C)[C@@]2([H])C[C@H]4[C@]5(O4)[C@@]36[C@@H](O6)[C@H](O7)[C@@]7(C(O)(C)C)[C@H]5OC(CCCCOC8=NON=C8S(=O)(C9=CC=CC=C9)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 310 Related Classifications
HY-182284 Related Classifications
Powered by Bioz
- Anticancer agent 310
- Anticancer agent310
- Anticancer agent-310
- Reactive Oxygen Species (ROS)
- Apoptosis
- Bcl-2 Family
- Caspase
- SHMT
- Methylenetetrahydrofolate Dehydrogenase (MTHFD)
- Cytochrome P450
- GSH/GSSG
- xenograft mouse models
- SHMT2
- Bax/Bcl-2
- Cyt c
- Caspase-9
- Caspase-3
- apoptotic pathway
- MTHFD2
- folate one-carbon metabolism
- AGS cells
- gastric cancer cells
- redox homeostasis
- NADPH/NADP+
- Inhibitor
- inhibitor
- inhibit